DK4146659T3 - Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria - Google Patents

Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria Download PDF

Info

Publication number
DK4146659T3
DK4146659T3 DK21724674.3T DK21724674T DK4146659T3 DK 4146659 T3 DK4146659 T3 DK 4146659T3 DK 21724674 T DK21724674 T DK 21724674T DK 4146659 T3 DK4146659 T3 DK 4146659T3
Authority
DK
Denmark
Prior art keywords
fused
prevention
preparation
treatment
ring
Prior art date
Application number
DK21724674.3T
Other languages
Danish (da)
English (en)
Inventor
Fredrik Almqvist
Pardeep Singh
Original Assignee
Quretech Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quretech Bio Ab filed Critical Quretech Bio Ab
Application granted granted Critical
Publication of DK4146659T3 publication Critical patent/DK4146659T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK21724674.3T 2020-05-08 2021-05-07 Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria DK4146659T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2050543 2020-05-08
PCT/EP2021/062237 WO2021224501A1 (en) 2020-05-08 2021-05-07 Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria

Publications (1)

Publication Number Publication Date
DK4146659T3 true DK4146659T3 (en) 2025-04-14

Family

ID=75888058

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21724674.3T DK4146659T3 (en) 2020-05-08 2021-05-07 Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria

Country Status (8)

Country Link
US (1) US12503476B2 (https=)
EP (1) EP4146659B1 (https=)
JP (1) JP7741817B2 (https=)
CN (1) CN115551869B (https=)
DK (1) DK4146659T3 (https=)
ES (1) ES3017588T3 (https=)
PL (1) PL4146659T3 (https=)
WO (1) WO2021224501A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841559B1 (en) * 1999-11-19 2005-01-11 Washington University Of St. Louis Pyridinones to treat and prevent bacterial infections
WO2014185853A1 (en) 2013-05-14 2014-11-20 Quretech Bio Ab Compounds and methods for treatment of chlamydia infections
CN107074878B (zh) 2014-11-13 2019-12-24 快尔生物技术公司 2,3-二氢-噻唑并[3,2-a]吡啶-5-酮衍生物、其中间体及其作为抗细菌剂的用途
EP3439655B1 (en) * 2016-04-08 2021-03-03 Quretech Bio AB Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
EP3638681A1 (en) * 2017-06-13 2020-04-22 Quretech Bio AB Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria
CN111246848A (zh) * 2017-10-05 2020-06-05 快尔生物技术公司 与抗结核药物组合的环稠和的噻唑并2-吡啶酮

Also Published As

Publication number Publication date
EP4146659A1 (en) 2023-03-15
JP2023525280A (ja) 2023-06-15
EP4146659B1 (en) 2025-02-26
WO2021224501A1 (en) 2021-11-11
US12503476B2 (en) 2025-12-23
CN115551869A (zh) 2022-12-30
ES3017588T3 (en) 2025-05-13
JP7741817B2 (ja) 2025-09-18
PL4146659T3 (pl) 2025-06-23
CN115551869B (zh) 2024-01-02
US20230339973A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
WO2009088549A3 (en) Methods of inhibiting bacterial virulence and compounds relating thereto
IL268960A (en) 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PH12018501221A1 (en) Mixture of hmos
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
PT2748165T (pt) Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas
WO2016109684A3 (en) Derivatives and methods of treating hepatitis b infections
BR112012001987A2 (pt) Composto, combinação, formulação farmacêutica, uso de um composto, uma combinação ou um sal farmaceuticamente aceitável dos mesmos, e, métodos para tratar uma infecção bacteriana, para matar ou inibir o crescimento de uma bactéria, e para inibir uma beta-lactamase.
PH12019500083A1 (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
IL289164A (en) The history of imidazo[2,1-a)pyridinyl and their use in the treatment of diseases
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
SG10202002898RA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
PH12018502297A1 (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
WO2015110969A3 (en) Nitrogen containing compounds and their use as antibacterial agents
ZA202008040B (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
DK3292867T3 (da) Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
IL312625A (en) Crystalline compounds of imidazo[5,4-b]pyridine, pharmaceutical compositions, and their uses in the treatment of medical conditions
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
CN110062806A (zh) 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
DK4146659T3 (en) Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria